Efficient gene disruption with CRISPR-Cas3 in human T cells

Area of Science:

• Molecular Biology
• Gene Editing Technologies
• Immunotherapy

Background:

• CRISPR-Cas9 is a versatile genome editing tool but faces safety challenges like off-target mutations and chromosomal rearrangements.
• Clinical applications of CRISPR-Cas9 are limited by these safety concerns.
• CRISPR-Cas3, a Class 1 CRISPR system, shows promise as a safer alternative with reduced off-target activity.

Purpose of the Study:

• To evaluate the efficacy and safety of the CRISPR-Cas3 system for genome editing in human T cells.
• To assess the potential of CRISPR-Cas3 in developing advanced T cell-based therapies.
• To compare the off-target effects of CRISPR-Cas3 with CRISPR-Cas9.

Main Methods:

• Application of the CRISPR-Cas3 system to human T cells.
• Targeted disruption of T cell receptor alpha constant (TRAC) and beta-2 microglobulin (B2M) genes.
• Analysis of gene deletions, off-target mutations, and CAR-T cell functionality.

Main Results:

• Successful disruption of TRAC and B2M genes in human T cells using CRISPR-Cas3.
• Gene deletions reduced graft-versus-host disease risk and host immune rejection.
• No off-target mutations were detected in CRISPR-Cas3-edited cells, unlike CRISPR-Cas9.
• CRISPR-Cas3-edited CAR-T cells maintained tumor cell cytotoxicity and showed reduced alloreactivity.

Conclusions:

• CRISPR-Cas3 is a safer and effective genome editing platform for T cell engineering.
• This system holds significant potential for next-generation allogeneic T cell therapies.
• CRISPR-Cas3 offers a promising alternative to CRISPR-Cas9 for clinical applications in immunotherapy.